Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation
Original languageEnglish
Pages (from-to)1637-1645
Number of pages9
JournalThe Lancet
Volume397
Issue number10285
Early online date29 Apr 2021
DOIs
Publication statusPublished - 7 May 2021

Fingerprint Dive into the research topics of 'Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial'. Together they form a unique fingerprint.

Cite this